

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SinoMab BioScience Limited**

**中國抗體製藥有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 3681)**

## **INSIDE INFORMATION SHARES DEALING BY A SUBSTANTIAL SHAREHOLDER**

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

On 7 December 2020, SinoMab BioScience Limited (中國抗體製藥有限公司) (the “**Company**”) was informed by Forbest Capital Investment Group Limited (“**Forbest Capital**”), a substantial shareholder of the Company, that Forbest Capital has entered into an agreement to dispose of a total of 89,802,105 shares of the Company (the “**Share(s)**”), representing approximately 8.92% of issued share capital of the Company, to an independent third party, Ms. XU Sijia (許斯佳) at a price of HK\$3.01 per Share for a total consideration of approximately HK\$270,304,336 (the “**Transaction**”). The consideration per Share was based on the average closing price in the 5 trading days immediately prior to the Transaction. Upon the completion of the Transaction, Forbest Capital is interested in 61,500,740 Shares, representing approximately 6.11% equity interests in the Company and has ceased to be a substantial shareholder of the Company (as defined under the Listing Rules) and Ms. XU Sijia (許斯佳) is interested in 89,802,105 Shares, representing approximately 8.92% equity interests in the Company.

By Order of the Board  
**SinoMab BioScience Limited**  
**Dr. Shui On LEUNG**

*Executive Director, Chairman and Chief Executive Director*

Hong Kong, 7 December 2020

*As at the date of this announcement, the executive Director is Dr. Shui On LEUNG, the non-executive Directors are Dr. Haigang CHEN, Mr. Xun DONG, Mr. Senlin LIU, Ms. Wenyi LIU, Mr. Huiyuan MA and Mr. Jing QIANG, and the independent non-executive Directors are Mr. George William Hunter CAUTHERLEY, Mr. Michael James Connolly HOGAN, Mr. Ping Cho Terence HON and Mr. Dylan Carlo TINKER.*